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Alcohol synergistically enhances the progression of liver disease and
the risk for liver cancer caused by hepatitis C virus (HCV). However,
the molecular mechanism of this synergy remains unclear. Here, we
provide the first evidence that Toll-like receptor 4 (TLR4) is induced by
hepatocyte-specific transgenic (Tg) expression of the HCV nonstruc-
tural protein NS5A, and this induction mediates synergistic liver
damage and tumor formation by alcohol-induced endotoxemia. We
also identify Nanog, the stem/progenitor cell marker, as a novel
downstream gene up-regulated by TLR4 activation and the presence
of CD133/Nanog-positive cells in liver tumors of alcohol-fed NS5A Tg
mice. Transplantation of p53-deficient hepatic progenitor cells trans-
duced with TLR4 results in liver tumor development in mice following
repetitive LPS injection, but concomitant transduction of Nanog short-
hairpin RNA abrogates this outcome. Taken together, our study dem-
onstrates a TLR4-dependent mechanism of synergistic liver disease by
HCV and alcohol and an obligatory role for Nanog, a TLR4 downstream
gene, in HCV-induced liver oncogenesis enhanced by alcohol.
Chronic liver damage caused by viral infection, alcohol, meta-bolic syndrome, or these factors in combination can increase
the risk for hepatocellular carcinoma (HCC), which is the fifthmost
common cancer in the world (1). In particular, chronic infection
with hepatitis B virus (HBV) or hepatitis C virus (HCV) represents
a major risk factor for HCC (1). HCV infects more than 170million
people worldwide (1–3). Ample epidemiological evidence suggests
that there is a strong connection between HCV and alcoholic liver
disease (ALD). First, the prevalence of HCV infection is signifi-
cantly higher among alcoholics than in the general population (4).
Second, the presence of HCV infection correlates with the severity
of the disease in alcoholic subjects, as such that HCV-infected
patients with ALD develop liver cirrhosis and HCC at significantly
accelerated rates than do uninfected ALD patients, suggesting that
alcohol and HCV work synergistically to cause liver damage (5).
Several possible mechanisms may explain the high prevalence of
HCV among alcoholics and the increased severity of liver diseases in
these patients. Alcohol may enhance the replication of HCV and
increase the expression of viral RNA and proteins, resulting in more
severeHCV-induced liver injury, and thismay in part explain a positive
correlationbetweenHCVtiterand theamountofalcohol consumption
(6). A metabolite and metabolic side-products of ethanol, such as
acetaldehyde and free radicals, may directly stimulateHCV replication
and gene expression (7, 8). Enhanced HCV replication may also be
indirectly caused by alcohol-induced immunosuppression (9).
Recent studies with mice expressing HCV proteins have shed
pivotal insight into the mechanisms underlying the synergism with
alcohol. The HCV core protein causes overproduction of reactive
oxygen species, which appears to be responsible for mitochondrial
DNA damage (10). The core protein also inhibits microsomal
triglyceride transfer protein activity and very low-density lipopro-
tein (VLDL) secretion (11), whichmay underlie the genesis of fatty
liver. The core protein also induces insulin resistance in mice and
cell lines, and this effect may be mediated by degradation of insulin
receptor substrates (IRS) 1 and 2 via up-regulation of SOCS3 (12)
in a manner dependent on PA28 73 or via IRS serine phosphor-
ylation (13). Thus, these core-induced perturbations, such as oxi-
dant stress and insulin resistance, which are also known risk factors
for ALD, may contribute to the synergism reproduced in alcohol-
fed core transgenic mice (14).
The most devastating consequence of the synergism between
viral hepatitis and alcohol is HCC (15–19). The risk of developing
HCC as assessed by odds ratio increases from 8 to 48 by having
concomitant alcohol abuse in HCV- and/or HBV-infected patients
(19). Although the effects of the core described above may con-
tribute to this synergism, we directed our attention to the HCV
nonstructural protein NS5A as a potential effector for the syner-
gism. NS5A is known to have a cryptic trans-acting activity for
cellular gene promoters (20) and to interact with an IFN-induced,
double-stranded RNA-activated protein kinase PKR (21), thus
accounting for the resistance of most HCV strains to IFN treat-
ment. Our recent study revealed that NS5A expression induces
TLR4 in the B cell lymphoma cell line Raji and the hepatoma cell
line Huh7 (22). This result raised a possibility that NS5A-induced
TLR4 may aggravate ALD, which is known to be mediated by
endotoxin, the ligand for TLR4. Indeed, the present study provides
direct mechanistic evidence that hepatocyte-specific transgenic (Tg)
expression of the HCV nonstructural protein NS5A up-regulates
TLR4, which in turn induces severe steatohepatitis and liver tumors
when this pattern recognition receptor is activated by alcohol-induced
endotoxemia. Further, our research identifies the stem cell marker
Nanogas adirect downstreamgene required forTLR4-dependent liver
oncogenesis.
Results
NS5A Induces TLR4 Expression in the Mouse Liver. We have shown
previously that NS5A induces the expression of TLR4 in the B cell
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lymphoma cell line Raji and the hepatoma cell line Huh7 (22).
However, whether NS5A induces TLR4 in the liver of the whole
animal is yet to be determined. To address this question, NS5A was
expressed in a hepatocyte-specific manner in mice with the use of
an apoE promoter (23, 24). RT-PCR and immunoblot analyses
confirmed induction of TLR4 mRNA and protein levels in the
NS5A Tg mouse liver compared with the wild-type (WT) mouse
liver (Fig. 1 A and B). Expressions of p53, Noxa, and -tubulin
mRNA were not different between the 2 groups (25, 26). These
results demonstrate in vivo induction of hepatic TLR4 expression
by NS5A and support the rationale for testing the role of TLR4 in
synergistic liver damage by alcohol and HCV NS5A.
LPS Induces Fulminant Hepatitis and Mortality in NS5A Tg Mice in a
TLR4-Dependent Manner. To test the functionality of NS5A-induced
TLR4, we created 4 genetic mouse lines with the identical back-
ground C57BL/6: (i) WT mice (WT); (ii) WT mice with TLR4
deficiency (Tlr4/); (iii) NS5ATgmice (NS5A); and (iv) NS5ATg
mice with TLR4 deficiency (Tlr4/NS5A). These mice were
challenged by intraperitoneal injection of an acute sublethal dose of
LPS (25 mg/kg). This challenge expectedly and markedly raised the
serum levels of aspartate aminotransferase (AST) and TNF- in
WT, whereas these parameters were significantly attenuated in
Tlr4/ (Fig. 1 D and E). LPS-challenged WT mice did not show
conspicuous liver pathology (Fig. 1C Top) or mortality [supporting
information (SI) Fig. S1A]. In contrast, in NS5A Tg mice, LPS
caused 30%mortality (Fig. S1A), fulminant hepatitis characterized
by massive hemorrhagic liver necrosis and inflammation (Fig. 1C
Middle), and augmented elevations of serumAST and TNF- (Fig.
1D andE). Importantly, all of these changes were largely abrogated
inTrl4/NS5Amice (Fig. 1C–E andFig. S1A), supporting the role
of TLR4 in LPS-induced hepatitis and mortality in NS5A mice.
Next, we validated whether NS5A expression augmented LPS-
induced signal transduction via TLR4 by assessing the interaction
of TGF--activated kinase 1 (TAK1) with TNFR-associated factor
6 (TRAF6) or IL-1 receptor-associated kinase-1 (IRAK1), the
signaling events immediately downstream of LPS-TLR4-CD14
binding (13). Coimmunoprecipitation analysis of liver protein ex-
tracts readily detected enhanced TAK1–TRAF6 and TAK1–
IRAK1 interactions in NS5A mice given LPS, whereas these
protein–protein interactions were not observed in WT or Tlr4/
NS5A mice under the same immunoblotting condition (Fig. 1F).
We also analyzed phosphorylation of JNK and IB, 2 further
downstream parameters of TLR4 signaling. As shown in Fig. 1G,
phosphorylation of JNK and IB (p-JNK, p- IB) was also
prominent in NS5Amice but not inWTor Tlr4/NS5Amice (Fig.
1G). These results demonstrate augmented activation of TLR4
signaling in the liver of LPS-challenged NS5A mice and their
sensitization for LPS-induced fulminant hepatitis.
Because TLR4 was primarily induced in hepatocytes by
hepatocyte-specific expression of NS5A, the accentuated liver
damage in NS5A mice is presumed to have resulted from
heightened TLR4 activation in the parenchymal cells. However,
Kupffer cells still represent another obvious cellular site of TLR4
signaling. Thus, to determine whether or to what extent Kupffer
cells contribute to liver injury induced by LPS in NS5A mice, we
depleted Kupffer cells by administration of liposome-
encapsulated Clodronate (27) 2 days before LPS injection. This
method depletes more than 95% of Kupffer cells (27) and largely
(7580%) prevented LPS-induced increases in serum AST and
TNF- levels in WT, confirming that Kupffer cells are the
predominant site of TLR4 activation. In NS5A, however, the
same manipulation reduced these parameters only by 35% and
39%, respectively (Fig. S1 B and C) and did not attenuate the
mortality rate (data not shown). From these results, we conclude
that Kupffer cell-derived TNF- accounted for 40% of total
TNF- produced in response to LPS in NA5A mice and had a
only minor if no role in liver damage and mortality in this model.
Conversely, these results suggest that the remaining 60% of
TNF- in the serum of these mice was produced by TLR4-
expressing hepatocytes.
Expression of NS5A and TLR4 in Hepatitis C Patient Livers. Next, we
assessed the clinical relevance of our finding on TLR4 induction in
NS5A mice. Liver protein extracts were obtained from healthy
subjects, patients with HCV infection, and HCV patients with a
history of alcoholism. These samples and the samples from NS5A
mouse livers were concomitantly analyzed for the expression of
NS5A by immunoblot analysis. As shown in Fig. S2A, the expres-
sion of NS5A is increased in HCV patients with or without
alcoholism compared with healthy subjects. A densitometric anal-
Fig. 1. Increased susceptibility of NS5A transgenic mice to endotoxin chal-
lenge. (A and B) TLR4 mRNA and protein expressions in the liver of NS5A Tg
mice were increased, as demonstrated by RT-PCR (A) and Western blot (B)
analyses. (C) H&E-stained sections of livers collected 24 hours after LPS chal-
lenge (25 mg/kg weight, intraperitoneally) showed coagulative necrosis with
hemorrhage in NS5A Tg mice (Middle) but no histological abnormality in
wild-type mice (WT, Top) or NS5A Tgmice with TLR4 deficiency (Tlr4/NS5A,
Bottom) (Magnification: 100). (D) Serum AST levels at 24 hours after LPS
challenge. TLR4 deficiency (Tlr4/) attenuated LPS-induced elevation of AST
compared with wild-type mice (WT; *, P  0.05). NS5A Tg mice showed an
augmentedAST elevation comparedwithWT (*, P 0.05), and this effect was
abrogated by TLR4 deficiency (Tlr4/NS5A) (*, P  0.05). (E) Time course
changes in serum TNF- level after LPS injection. Increased TNF- levels in WT
were reduced in Tlr4/ (*, P  0.05) but augmented in NS5A mice (**, P 
0.05). Heightened TNF- levels in NS5A mice were abrogated in Tlr4/NS5A
(***, P 0.05). (F) LPS-induced signaling, such as TAK1 interactionwith TRAF6
or IRAK, was enhanced in NS5A but not Tlr4/NS5A mice. (G) LPS-induced
phosphorylation of JNK and IB in the liver was increased in NS5A but not
Tlr4/NS5A mice.
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ysis of normalizedNS5Aexpression shows that the expression in the
patient livers is about a third of the level seen in NS5A mice (Fig.
S2B). These results indicate that NS5A Tg expression in our mouse
model is not extremely unphysiological. Next, we performed im-
munocytochemistry on liver cryosections from HCV patients with
or without alcoholism to assess the expression of TLR4 and 2
downstream parameters of TLR4 signaling: p-JNK and p-IB. In
these samples, increased colocalization of TLR4 with p-JNK and
p-IB was noted, particularly in HCV patients with alcoholism
(Fig. S2D andE). These results support the clinical relevance of our
finding on TLR4 induction and activation in NS5A mice.
NS5A-Induced TLR4 Aggravates Alcoholic Steatohepatitis. Because
NS5A mice are sensitive to LPS due to TLR4 induction, and
alcohol-induced liver injury is known to be mediated by endotoxin,
we tested whether NS5A Tg mice are more susceptible to alcohol-
induced liver damage. For this, the same 4 genetic lines of mice
described above (WT, Tlr4/, NS5A, and Tlr4/NS5A) were fed
either control or ethanol diet by intragastric infusion that allowed
maximal ethanol intake for 4 weeks (see experimental design in Fig.
S3A). Ethanol feeding in WT mice resulted in diffuse (24)
fatty liver with or without small foci of inflammation (Table S1) and
a 2.7-fold increase in plasma alanine aminotransferase (ALT) levels
(95  18 units/L) compared with control diet-fed WT mice (Fig.
S3B). In contrast, ethanol-fed NS5A Tg mice displayed an addi-
tional 2-fold increment in ALT elevation (181  21 units/L)
compared with ethanol-fed WT mice (Fig. S3B). Spotty and
submassive liver necrosis, as well as infiltration of mononuclear
cells, neutrophils, and eosinophils in the necrotic midzone region,
was also observed in these mice (Fig. S3G). This pathology resem-
bles coagulative necrosis commonly observed in chronically
ethanol-fed rodents given acute LPS and confirmed that NS5A Tg
mice are more susceptible to alcoholic steatohepatitis. This pathol-
ogy and the elevation of the plasma ALT level were largely
abolished in Tlr4/NS5A mice (Table S1 and Fig. S3 D and H),
confirming the pathogenic role of TLR4 in this mouse model. It
should be noted that the plasma endotoxin levels in NS5A Tg and
WT mice were equally elevated by alcohol feeding compared with
pair-fed control animals (Fig. S3C).
Next, we determined the role of endotoxin in alcoholic steato-
hepatitis in NS5A Tg mice by intragastric administration of poly-
myxin B (150mg/kg per day) and neomycin (450mg/kg per day) for
4 days before alcohol feeding and during the entire feeding period.
This antibiotic treatment reduced ALT levels (Fig. S3E) and liver
pathology in ethanol-fed NS5A Tg mice (Fig. S3I and Table S1).
Conversely, LPS was administered weekly via the intragastric tube
to ethanol-fed NS5A Tg mice to test whether this manipulation
accentuates alcoholic liver damage. As expected, LPS aggravated
liver damage caused by alcohol (Table S1) and led to 2.5-fold higher
serum ALT levels compared with alcohol-fed NS5A mice without
LPS (Fig. S3E). These results indicate the importance of endotoxin-
activated TLR4 signaling in the pathogenesis of aggravated steato-
hepatitis in alcohol-fed NS5A Tg mice. Oxidant damage is a key
feature of alcoholic liver damage that can be further potentiated by
endotoxin (28, 29). Thus, we measured the hepatic content lipid
peroxides in WT and NS5A Tg mice fed alcohol or control diet.
Alcohol feeding increased the lipid peroxide levels 2-fold in WT
mice. In NS5A Tg mice, this effect was significantly accentuated
with a 3.3-fold elevation, indicating enhanced oxidative damage in
alcohol-fed NS5A Tg mice (Fig. S3J).
NS5A-Induced TLR4 Causes Synergistic Liver Oncogenesis by Long-
Term Alcohol Feeding. We next extended our study to determine
whether NS5A-mediated TLR4 induction causes liver tumor after
prolonged alcohol feeding. For this experiment, we fed the same 4
genetic lines of mice Lieber-DeCarli diet containing 3.5% (wt/vol)
ethanol or isocaloric dextrin for 12 months. This liquid diet con-
taining the lower ethanol concentration was fed ad libitum, and this
regimen alleviated the high mortality commonly associated with
this type of long-term feeding. Total daily caloric intakes from the
control or ethanol diet by different genetic groups were not
significantly different (WT: 17.2  3.4 vs. 15.3  2.8, Tlr4/:
18.1  3.1 vs. 16.1  4.4, NS5A: 18.1  4.1 vs. 15.7  3.0, and
Tlr4/NS5A: 17.6  3.6 vs. 16.3  4.0 mL/mouse per day). Liver
tumor was not detected inWT,NS5ATg, or Tlr4/NS5Amice fed
the control diet or WT mice fed the alcohol diet. In contrast, liver
tumor was found in 23% of ethanol-fed NS5A Tg mice (Fig. 2 and
Table S2) but was completely absent in Tlr4/NS5A Tg mice
(Table S2). Most tumors detected in NS5A mice were hepatoma
(Fig. 2). WT and NS5A mice studied for this experiment had
relatively even sex distributions (49% and 55% females vs. 51% and
45% males), and the tumor incidence was not statistically different
between the 2 sexes (Table S3). Alcohol feeding increased serum
TNF- levels 4-fold in WT mice and 6-fold in NS5A Tg mice, and
this difference was significant (Table S2). TLR4 deficiency signif-
icantly and largely attenuated this increment in alcohol-fed NS5A
mice (Table S2). Enhanced TLR4 signaling by NS5A and alcohol
feeding was validated by increased TAK1 interaction with TRAF6
and by elevated p-JNK and p-IB in the livers of alcohol-fed NS5A
mice but not alcohol-fed WT or Tlr4/NS5A mice (Fig. S4 A and
B). Colocalization of TLR4with TNF-, p-IB, and p-JNKwas also
evident in liver sections of alcohol-fedNS5A but notWTmice (Fig.
S4 C and D). These data demonstrate that alcohol and NS5A
synergistically induce liver tumors through enhanced expression of
TLR4 and signaling.
Nanog as a TLR4 Downstream Gene Induced by NS5A and Alcohol. To
understand the molecular mechanisms of the synergism demon-
strated in alcohol-fed NS5A mice, we performed microarray anal-
ysis onRNAsamples extracted fromnon-tumor-bearing portions of
liver tissues from NS5A Tg and WT mice fed alcohol as described
in detail in SIMethods. Ofmore than 39,000 transcripts and variants
examined by using more than 45,000 probe sets, 83 transcripts
showed increased expression with a cutoff value of 4.0-fold (bal-
anced differential expression) in NS5A mouse livers. The lists of
differentially regulated genes are shown in Fig. S5. Of note are
induction of a stem cell marker (i.e., Nanog), TLR4 downstream
cytokines (e.g., IFN-4), and apoptosis-related genes (e.g., Bcl2a1a
and Bcl11a) as well as down-regulation of the epigenetic transcrip-
tional regulator trithorax group of proteins (e.g., ASH1 and ASH2)
and developmental transcription factors (e.g., Hox, Myo, and Fox
families).
Induction of the stem cell marker Nanog in alcohol-fed NS5A
mice was intriguing in light of the report that a particularly poor
prognostic subtype of human HCC is derived from hepatic pro-
genitor cells (30). This induction was confirmed by immunofluo-
rescence microscopy (Fig. 3A), immunoblotting (Fig. 3B), and
quantitative RT-PCR (Fig. 3C). Nanog was colocalized with an-
other stem cell marker, CD133 or CD49f, in liver tumors of NS5A
Tg mice fed alcohol (Fig. 3A), suggesting the presence of cancer
stem cells. Nanog induction was dependent on NS5A and alcohol
(Fig. 3 B and C) and abrogated in Tlr4/NS5A mice fed alcohol
Fig. 2. HCV NS5A induced liver tumors after 12-month alcohol feeding, as
shown in this representative photograph (Left) of gross liver appearance and
a microphotograph (Right) of an H&E-stained section of the tumor. (Magni-
fication: 100).
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(Fig. 3C).We next tested the direct relationship of Nanog induction
withTLR4activation by analyzingNanog expression inLPS-treated
Huh7 cells transduced with an NS5A or control vector with or
without TLR4 knockdown with short-hairpin RNA (shRNA). As
shown in Fig. 3D, LPS up-regulated Nanog expression in NS5A-
transduced cells but not in control vector-transfected cells. This
induction of Nanog by LPS was significantly reduced by shRNA
directed against TLR4 but not by scrambled shRNA (Fig. 3D). To
assess the efficiency of TLR4 knockdown, we performed immu-
noblot analysis. As shown in Fig. 3E, induction of TLR4 protein by
NS5A was decreased approximately by 80% with TLR4 shRNA.
Overexpression of Tlr4 (TLR4) but not the mutant with deletion
of the cytoplasmic domain (TLR4Cyt) in Huh7 cells also in-
creased the expression of Nanog in the presence of LPS, further
validating that activated TLR4 enhances Nanog expression (Fig.
3D). To determine whether NS5A induces Nanog expression via
TLR4 at the transcriptional level, we performed a reporter assay
using a Nanog promoter. LPS treatment increased the reporter
activity in the cells transduced with NS5A. This induction was
attenuated with TLR4 shRNA but not with control shRNA (Fig.
3F). Transduction of wild-type TLR4 but not themutant TLR4 also
caused the promoter activation in the presence of LPS. These
results demonstrate that the promoter of the Nanog gene is directly
activated by TLR4, andNanog is a novel downstream gene of TLR4
signaling.
Nanog Mediates TLR4-Dependent Liver Oncogenesis by Hepatic Pro-
genitor Cells. To further validate the role of TLR4 and Nanog in
liver oncogenesis in the whole animal, we used the hepatic
progenitor cell transplantation model (31). Hepatoblasts were
isolated from p53-deficient embryonic livers (embryonic days
12.515), infected with a retroviral vector expressing TLR4 or
Nanog along with GFP, and transplanted into wild-type mice via
splenic injection. These recipient mice were injected with 3 doses
of the hepatotoxin CCl4 to stimulate reconstitution of trans-
planted progenitor cells in the liver and were subsequently
treated by repetitive intraperitoneal injection of LPS or PBS 3
times a week for 25 weeks (Fig. 4A). The cells transduced with
a c-myc expression vector served as a positive control, which led
to consistent liver tumor formation (Fig. 4 B and C). Mice
receiving a transplant of TLR4-transduced progenitor cells
developed liver tumors after 48–54 days following transplanta-
tion only when LPS was administered (Fig. 4 B and C), as judged
by GFP imaging of the animals (Fig. 4D) and autopsy. No tumor
was observed in mice receiving a transplant of the cells trans-
duced with the TLR4 deletion mutant of cytoplasmic domain
(Cyt), even after LPS injection (Fig. 4C). The tumor incidence
caused by TLR4 transduction and LPS injection was reduced by
coexpression of shRNA against Nanog but not scrambled
shRNA (Fig. 4 B and C). Direct Nanog transduction in hepatic
progenitor cells also produced liver tumors, but to a lesser extent
compared with the LPS-injected mice with transplantation of
TLR4-transduced cells (Fig. 4 B and C, TLR4  LPS). The
mortality of the mice in the different treatment groups roughly
correlated with the liver tumor incidence (Fig. 4E).
To further assess the appearance and growth rate of tumors
caused by the TLR4- or Nanog-transduced progenitor cells,
the cells were injected s.c. into nude mice, and GFP imaging
was performed for quantitative assessment of the tumor
volume every 8 days for 88 days. TLR4-transduced cells began
to form a tumor mass at 40 days after transplantation only
when LPS was administered and the cells were deficient in p53
(p53/), but not when PBS was given or the transplanted cells
were from the wild-type mice (p53/) (Fig. 4F). The cells
transduced with the mutant TLR4 (Cyt) did not form tumors.
The tumor mass in the TLR4 plus LPS mice steadily grew in
size and was approximately half of that seen with c-Myc-
transduced cells at the terminal point (Fig. 4F). Nanog-
Fig. 3. (A) Confocal immunofluorescentmicroscopy
demonstrates colocalization of the stem cell marker
Nanog with CD133 or CD49f in the tumor-bearing
tissue from NS5A mice fed alcohol for 12 months.
(Magnification: 100.) (B) Nanog protein was in-
duced in the livers of NS5A mice fed alcohol, as
determined by immunoblot analysis. Immunoblot-
ting of -actin served as a loading control. (C) Nanog
mRNA was induced in the livers of NS5A mice fed
ethanol, as determined by real-time PCR (*, P  0.03
comparedwith ethanol-fedWTmice). This induction
was attenuated in ethanol-fed Tlr4/NS5A mice (*,
P  0.03 compared with ethanol-fed NS5A). (D) LPS
induced Nanog mRNA in Huh7 cells transduced with
an NS5A expression vector (*, P  0.002 compared
with the cells transduced with the empty vector and
control shRNA). This induction was suppressed by
retroviral expression of shRNA for TLR4 (**, P 
0.05). Nanog mRNA also was induced by LPS treat-
ment in the cells transduced with a retroviral vector
expressing wild-type TLR4 (TLR4, *, P  0.05 com-
pared with the control cells), but not in the cells
transducedwith themutant TLR4 vector (TLR4Cyp).
(E) Efficient knockdown of TLR4 with the retroviral
shRNA vector is evident in this immunoblot analysis
and densitometric analysis revealing an 82% reduc-
tion (*, P  0.05). (F) LPS added to the culture acti-
vated the Nanog promoter in Huh7 cells transfected
with the promoter-luciferase construct (*, P  0.002
compared with the control cells). TLR4 knockdown
with shRNA as above abrogated the promoter acti-
vation (**, P  0.05). Expression of wild-type TLR4
(TLR4, *, P 0.05) but not mutant TLR4 (TLR4Cyp)
conferred the cells LPS-induced Nanog promoter activation. Relative light unit values were normalized by the activity of the Renilla luciferase construct
driven by SV40 promoter as a transfection control.
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transduced cells formed a detectable tumor mass in the
absence of p53, but at a later time point and with a lesser
growth rate (Fig. 4G). To determine whether Nanog expres-
sion induced by TLR4 signaling is essential for tumor forma-
tion and growth in this model, shRNA for Nanog was cotrans-
duced with the TLR4 expression vector. The tumor mass
appearance and growth by TLR4-trasnduced, p53/ progen-
itor cells were significantly delayed by Nanog shRNA compared
with those with scrambled shRNA (Fig. 4H). Silencing of Nanog was
confirmed by immunoblot analysis of the cells collected 10 days after
transplantation (Fig. 4H Inset). These results indicate that Nanog
mediates the oncogenic potential of activated TLR4, but it alone does
not confer the full oncogenic effect.
Discussion
The present study reveals several novel findings with respect to the
molecular mechanism underlying synergistic liver pathology caused
by HCV and alcohol. First, it demonstrates that NS5A and alcohol
synergistically induce hepatocellular damage and transformation
via accentuated and/or sustained activation of TLR4 signaling,
which results from HCV NS5A-induced TLR4 and endotoxemia
associated with alcohol consumption. Second, Nanog is identified
as a novel downstream gene transcriptionally induced by activated
TLR4 signaling. Third, this stem cell marker is largely responsible
for TLR4-mediated liver tumor development, as shown by our
hepatic progenitor cell transplantation experiments. Last, despite
the common understanding that TLR4 is one of the pattern
recognition receptors expressed predominantly by innate immune
cells, such as macrophages and lymphocytes, our study demon-
strates that hepatocytes can be the primary cellular site of both
TLR4 up-regulation and its pathologic consequences in the context
of HCV infection. Our experiment with Kupffer cell depletion
shows a reduction of serum TNF- levels by 80% in WT mice but
only 40% in NS5A Tg mice given LPS (Fig. S1), indicating the
presence of amajor non-Kupffer cell source of TLR4 activation and
TNF- expression in NS5A Tg mice. This conclusion and its
relevance to humans are also supported by immunohistochemical
colocalization of TLR4 with p-JNK and p-IB in the liver paren-
chyma of HCV patients. Indeed, this new paradigm offers a logical
explanation for a clinical observation that hepatocytes are positively
stained for proinflammatory gene expression inHCVpatients (35).
Nanog transduction alone is not as effective as TLR4 activation
in liver tumorigenesis, as shown by our cell transplantation exper-
Fig. 4. TLR4-dependent development of
liver tumors by hepatoblast transplantation.
(A) A schematic diagram depicting the gener-
ation of liver tumors following retroviral
transduction of TLR4 in purified E-cadherin
hepatoblasts from p53/ mice, transplanta-
tion and engraftment of the hepatoblasts in a
recipient C57BL/6 mouse, and repetitive LPS
injection. (B) Gross photographs of livers fol-
lowing transplantation of p53/ hepato-
blasts transduced with c-Myc, Tlr4, Nanog,
shRNA for Nanog, or scrambled shRNA and 25
weeks of LPS treatment (2mg/kg, intraperito-
neally, every other day, the mice with c-Myc-
transduced cells did not receive LPS). (C) Tu-
mor incidence of recipient mice after
transplantation of p53/ hepatoblasts trans-
duced with the indicated gene and/or shRNA.
Mice that were received a transplant of
p53/, c-Myc-transduced cells mostly devel-
oped liver tumors without LPS treatment. The
mice receiving a transplant of TLR4-trans-
ducedp53/ cells alsodeveloped liver tumors
at the incidence rate of 40% (*P  0.03). This
tumor incidence was suppressed by cotrans-
duction of Nanog shRNA but not control
scrambled shRNA (**, P 0.05 comparedwith
the cells transduced with control shRNA).
Transduction of Nanog without LPS injection
alsoproduced liver tumors, butwithmuch less
frequency (***, P  0.05 compared with
empty vector-transduced cells without LPS).
(D)GFP imagingof the tumor-bearing livers of
LPS-treated mice transplanted with p53/
hepatoblasts transduced with TLR4 plus
Nanog shRNA or control shRNA. (E) Survival
curves of mice after transplantation of the
cells transduced with the indicated gene
and/or shRNA. (F) Tumor volume measure-
ment was performed by 3-dimensional GFP
imaging of nude mice at various times following s.c. transplantation of p53/ hepatoblasts transduced with TLR4, a deletion mutant of cytoplasmic domain of
TLR4 (Cyt), or c-Myc. Note a progressive tumor growth with the c-Myc-transduced cells even without LPS treatment serving as a positive control. Liver tumors
arose and grew inmice receiving a transplant of TLR4-transduced cells in response to repetitive LPS injection but not without LPS injection. The cells transduced
with the mutant TLR4 failed to form a tumor mass. (*, P  0.05 compared with empty vector-transduced cells with LPS.) (G) Hepatoblasts (p53/) transduced
with aNanog or control retroviruswere subcutaneously transplanted into nudemice, and the tumormass growthwasmonitored as above. Immunoblot analysis
was performed on the transduced cells after 10 days following infection and just before transplantation. This analysis confirms the expression of Nanog (Inset).
Nanog-transduced progenitor cells led to a small but significantly increased tumormass comparedwith the cells transducedwith the control vector (*, P 0.05).
(H) Hepatic progenitor cells expressing TLR4gave rise togrowing tumors in nudemice repetitively injectedwith LPS, and this growthwas significantly attenuated
withNanog shRNA (*,P0.04). Immunoblottingof lysates from thehepatoblasts collected10days after the transplantationandLPS injection confirms induction
of Nanog in TLR4-transduced cells and effective knockdown of Nanog by cotransduction of the specific shRNA (Inset).
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iment.We believe that TLR4 activation induces other tumor-driver
genes, which cooperatively work with Nanog to cause liver onco-
genesis. Thus, Nanog is still essential for TLR4-dependent onco-
genesis, but it alone is poorly oncogenic. In our previous work using
the Huh7 cell line, we demonstrated that TLR4 promoter up-
regulation byNS5A ismediated by PU.1, Oct-1, andAP-1 elements
(22). The similar transcriptional mechanism may underlie TLR4
induction in primary hepatocytes. Obviously, our future study will
need to address this possibility.
The roles of JNK and IKK in liver oncogenesis are important
questions. AP-1 is activated in bothHCCand chronic hepatitis (32).
In vitro studies using liver-derived cell lines demonstrate rapid
activation of AP-1 by HBV or HCV proteins (33). Our study also
shows activation of JNK in alcohol-fed NS5A Tg mice in concur-
rence with the increased risk of liver tumors (Fig. S4). Our study did
not address which isoform of JNK (JNK1/2) is responsible for
NS5A-TLR4-mediated liver damage and oncogenesis, and this is an
obvious question that will need to be addressed by our future study.
In summary, the present study has demonstrated that alcohol and
HCV NS5A induce synergistic liver tumor development via induc-
tion and activation of TLR4 in mice. The importance of Nanog as
a direct downstreamgene of TLR4 in this oncogenesis has also been
identified. These findings indicate that pharmacologic inhibition of
TLR4 signaling may provide a novel therapeutic option for HCV-
associated liver tumors.
Materials and Methods
Mice. Mice expressing the HCV NS5A gene under control of the apoE promoter
were obtained from Ratna Ray at Saint Louis University (St. Louis, MO). NS5A Tg
(FVB strain) and Tlr4/ mice on C57BL/6 strain (Jackson Laboratories) were
intercrossed more than 8 generations to produce WT, NS5A, Tlr4/, and Tlr4/
NS5A mice on a more congenic genetic background. Tsukamoto-French intra-
gastric ethanol infusion model was applied as previously described (34). Lieber–
DeCarli diet containing 3.5% ethanol or isocaloric dextrin (Bioserv) was fed for
long-term alcohol feeding. All animal experiments were performed with age-
and sex-matchedmice from same littermates and conducted in accordancewith
the approved Institutional Animal Care and Use Committee protocol at the
University of Southern California.
Hepatic Progenitor Cell Transduction and Transplantation Experiment. Hepato-
blast transplantation experiments were performed by using the protocol previ-
ouslydescribedfor isolation,culture, retroviral/lentiviral infection,andtransplan-
tationviaspleenofpurifiedp53/hepatoblasts (1106cells),aswellas retrosine
and CCl4 treatment and tumormonitoring of recipient C57BL/6mice (31). Tumor
volume (cm3) was calculated by the 3-dimensional animal imaging system at the
University of Southern California Molecular Imaging Center. For nude mouse
transplantation, Matrigel beads (Invitrogen) were used to anchor hepatoblasts
(2 106 cells) for s.c. injection.
ACKNOWLEDGMENTS.WethankQing-gaoDeng, JiaohongWang, SeanVorah,
and Jeffrey Huang (University of Southern California) for mouse experiments;
Michael Karin (University of California at SanDiego) for discussions; Paul Robson
(Genome Institute of Singapore, Immunos, Singapore) for Nanog-promoter lu-
ciferase construct; Steven Weinman (University of Texas) for suggestions; and
Moli Chen and Alex Trana for histological service. The study was supported by
pilot project funding; the Animal and Morphology Cores of the Southern Cali-
fornia Research Center for ALPD & Cirrhosis (P50 AA011999) funded by the
National InstituteonAlcoholAbuseandAlcoholism/National Institutes ofHealth
(NIAAA/NIH); NIH Grants AI 40038, CA123328, and CA108302; and the Medical
Research Service of the Veterans Administration.
1. Okuda K (2000) Hepatocellular carcinoma. J Hepatol 32:225–237.
2. Okuda MK, et al. (2002) Mitochondrial injury, oxidative stress, and antioxidant gene
expression are induced by hepatitis C virus core protein. Gastroenterology 122:366–
375.
3. Yao F, Terrault N (2001) Hepatitis C and hepatocellular carcinoma. Curr Treat Options
Oncol 2:473–483.
4. Heintges T, Wands JR (1997) Hepatitis C virus: Epidemiology and transmission. Hepa-
tology 26:521–526.
5. Brechot C, Nalpas B, Feitelson MA (1996) Interactions between alcohol and hepatitis
viruses in the liver. Clin Lab Med 16:273–287.
6. Oshita M, et al. (1994) Increased serum hepatitis C virus RNA levels among alcoholic
patients with chronic hepatitis C. Hepatology 20:1115–1120.
7. Choi J, et al. (2004) Reactive oxygen species suppress hepatitis C virus RNA replication
in human hepatoma cells. Hepatology 39:81–89.
8. Sawada M, Takada A, Takase S, Takada N (1993) Effects of alcohol on the replication
of hepatitis C virus. Alcohol Alcohol Suppl 1B:85–90.
9. Izzotti A, et al. (1998) DNA alterations in rat organs after chronic exposure to cigarette
smoke and/or ethanol ingestion. FASEB J 12:753–758.
10. Moriya K, et al. (2001) Oxidative stress in the absence of inflammation in a mouse
model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61:4365–
4370.
11. Perlemuter G, et al. (2002) Hepatitis C virus core protein inhibits microsomal triglyc-
eride transfer protein activity and very low density lipoprotein secretion: A model of
viral-related steatosis. FASEB J 16:185–194.
12. Kawaguchi T, et al. (2004) Hepatitis C virus down-regulates insulin receptor substrates
1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol
165:1499–1508.
13. Banerjee S, et al. (2008) Hepatitis C virus core protein upregulates serine phosphory-
lation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase
B signaling pathway for insulin resistance. J Virol 82:2606–2612.
14. Koike K, et al. (2008) Molecular basis for the synergy between alcohol and hepatitis C
virus in hepatocarcinogenesis. J Gastroenterol Hepatol 23(Suppl 1):S87–S91.
15. Donato F, Gelatti U, Limina RM, Fattovich G (2006) Southern Europe as an example of
interaction between various environmental factors: A systematic review of the epide-
miologic evidence. Oncogene 25:3756–3770.
16. Hassan MM, et al. (2002) Risk factors for hepatocellular carcinoma: Synergism of
alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213.
17. Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular
carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepa-
tology 43:1295–1302.
18. Peters MG, Terrault NA (2002) Alcohol use and hepatitis C. Hepatology 36:S220–S225.
19. Yuan JM, Govindarajan S, Arakawa K, Yu MC (2004) Synergism of alcohol, diabetes,
and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the
U.S. Cancer 101:1009–1017.
20. Kato N, Lan NH, Ono-Nita SK, Shiratori Y, Omata M (1997) Hepatitis C virus nonstruc-
tural region 5A protein is a potent transcriptional activator. J Virol 71:8856–8859.
21. Gale MJ, Jr, et al. (1997) Evidence that hepatitis C virus resistance to interferon is
mediated through repression of the PKR protein kinase by the nonstructural 5A
protein. Virology 230:217–227.
22. MachidaK, et al. (2006)Hepatitis C virus induces toll-like receptor 4 expression, leading
to enhanced production of beta interferon and interleukin-6. J Virol 80:866–874.
23. Majumder M, et al. (2003) Expression of hepatitis C virus non-structural 5A protein in
the liver of transgenic mice. FEBS Lett 555:528–532.
24. MajumderM,et al. (2002)Hepatitis C virusNS5Aprotein impairs TNF-mediatedhepatic
apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 294:94–105.
25. Kurata K, et al. (2008) Stress via p53 pathway causes apoptosis by mitochondrial Noxa
upregulation in doxorubicin-treated neuroblastoma cells. Oncogene 27:741–754.
26. Li J, Lee B, Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: Multiple
pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and
NOXA by p53. J Biol Chem 281:7260–7270.
27. Van Rooijen N, Kors N, vd Ende M, Dijkstra CD (1990) Depletion and repopulation of
macrophages in spleen and liver of rat after intravenous treatment with liposome-
encapsulated dichloromethylene diphosphonate. Cell Tissue Res 260:215–222.
28. Wu D, Cederbaum A (2008) Cytochrome P4502E1 sensitizes to tumor necrosis factor
alpha-induced liver injury through activation of mitogen-activated protein kinases in
mice. Hepatology 47:1005–1017.
29. Lu Y, Zhuge J, Wang X, Bai J, Cederbaum AI (2008) Cytochrome P450 2E1 contributes
to ethanol-induced fatty liver in mice. Hepatology 47:1483–1494.
30. Lee JS, et al. (2006) A novel prognostic subtype of human hepatocellular carcinoma
derived from hepatic progenitor cells. Nat Med 12:410–416.
31. Zender L, et al. (2006) Identification and validation of oncogenes in liver cancer using
an integrative oncogenomic approach. Cell 125:1253–1267.
32. Liu P, et al. (2002) Activation of NF-kappa B, AP-1 and STAT transcription factors is a
frequent and early event in human hepatocellular carcinomas. J Hepatol 37:63–71.
33. Kato N, et al. (2000) Activation of intracellular signaling by hepatitis B and C viruses:
C-viral core is the most potent signal inducer. Hepatology 32:405–412.
34. Tsukamoto H, Towner SJ, Ciofalo LM, French SW (1986) Ethanol-induced liver fibrosis
in rats fed high fat diet. Hepatology 6:814–822.
Machida et al. PNAS  February 3, 2009  vol. 106  no. 5  1553
M
IC
RO
BI
O
LO
G
Y
